retatrutide type 2 diabetes trial 2024 Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 for treatment of New clinical trial results show
Pay in 4 interest-free payments of $5.57 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5






























